Iceutica Pty Ltd.

Elan Pharma International Limited

Alkermes Pharma Ireland Limited

Nanosystems L.l.c.

Merck Sharp + Dohme Corp.

Sun Pharma Global Fze

Iceutica Inc.

Iceutica Py Ltd.

Iceutica Holdings Inc.

H William Bosch

Marck Norret

Felix Meiser

Adrian Russell

Aaron Dodd

Eugene Rex Cooper

Niels Peter Ryde

Kevin D Ostrander

Simon L McGurk

Gary G Liversidge

Rajeev A Jain

Douglas C Hovey

Matthew Callahan

Donna M Marcera

Jon R Swanson

Ronald L Mueller

Paul Nemeth

Lan DeCastro

Ray W Wood

John Dallas Pruitt

Pranab Bagchi

Stephen B Ruddy

John G Devane

Tuula Ryde

Scott Jenkins

Raymond P Scaringe

Robert G Reed

Elaine Liversidge

Christian F Wertz

David A Czekai

Kathleen J Illig

Laura Kline

Karen C Thompson

Maurice Joseph Anthony Clancy

Jon Swanson

Janet Elizabeth Codd

Robert Hontz

Elaine Merisko-Liversidge

Janine Keller

Kenneth Ian Cumming

Dinesh S Mishra

Maura Murphy

Suhas D Shelukar

Satya Bhamidipati

Jason Coleman

Matt Callahan

Christopher Hill

Greta G Cary

Tuula A Ryde

Robert W Lee

Rajeev Jain

Amy Walters

Douglas A White

A nanoparticulate composition of abiraterone acetate that allows treatment at a lower dose than convention abiraterone acetate formulations is described as in a method of treating prostate cancer by administering the composition together with a glucocorticoid.

Abiraterone steroid formulation

The present invention relates to methods for producing particles of indomethacin using dry milling processes as well as compositions comprising indomethacin, medicaments produced using indomethacin in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of indomethacin administered by way of said medicaments.

Formulation of indomethacin

Methods for making inhalable composite particles comprising a pharmaceutically-active agent, the method comprising: a) providing composite particles comprising a millable grinding matrix and a solid pharmaceutically-active agent, wherein the pharmaceutically-active agent has an median particle size on a volume average basis between 50 nm and 3 &#x3bc;m; and b) milling the composite particles in a mill without milling bodies for a time period sufficient to produce inhalable composite particles having a mass median aerodynamic diameter between 1 &#x3bc;m and 20 &#x3bc;m are described.

Inhalable pharmaceutical compositions

Pharmaceutical compositions, including unit dosage forms, comprising abiraterone acetate and methods for producing and using such compositions are described.

Abiraterone acetate formulation and methods of use

Unit dosage forms of meloxicam containing either 5 mg or 10 mg of meloxicam that provide effective pain relief and have desirable pharmacokinetic properties are described. The unit dosage forms can provide pain relief when a single unit dose is administered to a patient and useful for treating pain such as osteoarthritis pain at a relatively low systemic exposure to meloxicam.

Formulation of meloxicam

The present invention relates to methods for producing particles of diclofenac using dry milling processes as well as compositions comprising diclofenac, medicaments produced using diclofenac in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of diclofenac administered by way of said medicaments.

Formulation of diclofenac

Growing community of inventors

Bryn Mawr, PA, United States of America

H William Bosch